

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 1st July 2024

COMMUNICATION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

During the Ordinary General Meeting of Shareholders of FACEPHI BIOMETRÍA, S.A. (hereinafter, "FACEPHI" or the "Company"), held on 28th June 2024, at first call, with the attendance of a total of 19 shareholders, present or represented, and representing a total of 39,135% of the share capital, all the resolutions submitted to vote in accordance with the notice of the General Meeting published at the time were approved. The resolutions adopted are as follows:

FIRST: Examination and approval of the annual accounts (comprising the balance sheet, profit and loss account, statement of changes in equity, cash flow statement and notes), together with the management report for the year ended 31 December 2023.

The annual accounts of the Company for the year ended 31 December 2021 (comprising the balance sheet, the profit and loss account, the statement of changes in equity, the cash flow statement and the notes to the financial statements) together with the management report, as prepared by the Board of Directors of the Company on 30 April 2024.

Approved by majority.

SECOND: Examination and approval of the consolidated annual accounts (comprising the consolidated balance sheet, profit and loss account, statement of changes in equity, cash flow statement and notes to the financial statements, all of which are consolidated), together with the consolidated management report for the year ended 31 December 2023.

The consolidated annual accounts of the Group for the year ended 31 December 2023 (comprising the consolidated balance sheet, the consolidated income statement, the consolidated statement of changes in equity, the consolidated cash flow statement and the consolidated notes to the financial statements) together with the consolidated management report, as prepared by the Board of Directors of the Company on 30 April 2024.

Approved by majority.

THIRD: Examination and approval, as the case may be, of the proposal for the application of the Company's results corresponding to financial year 2023.

As indicated in the notes to the financial statements for fiscal year 2023, the Company has obtained a result for this fiscal year of - 2,327,198 euros. The proposal of the Board of Directors that is submitted to a vote consists of allocating this amount to offset "Negative results of previous years.

Approved by majority.

FOURTH: Examination and approval, as the case may be, of the management carried out by the Board of Directors of the Company for the financial year 2023.

The management of the Board of Directors during the financial year ended 31 December 2022 was approved by majority.

FIFTH: Approval, as the case may be, of the remuneration to be received by the executive officers of the Company, as well as by the members of the Board of Directors during the 2024 financial year.

The remuneration to be received by the Executive Director and by the members of the Board of Directors during the financial year 2024 is approved by majority.

SIXTH. - Appointment of NICE & GREEN SA, a company duly incorporated under the laws of Switzerland, with registered office at Avenue Reverdil 12, 1260 Nyon, Switzerland, as a member of the Board of Directors.

The appointment of Nice & Green, S.A. as proprietary director of the Company is approved by majority, as well as the appointment of Mr. Manuel Lanfossi, as the natural person designated to permanently perform the duties inherent to the position is approved by majority.

SEVENTH. - Delegation of Powers

It was approved by majority to delegate to the Chairman and the Secretary of the Board all the necessary procedures to make the agreements reached public.

And with no further business to discuss, the minutes were approved by the attendees.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors